Damora Therapeutics (DMRA) Total Current Liabilities (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Total Current Liabilities data on file, last reported at $23.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 1388.25% year-over-year to $23.8 million; the trailing twelve-month figure through Mar 2026 stood at $23.8 million (up 1388.25% YoY), and the FY2025 full-year result was $20.1 million, up 1575.0% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $23.8 million, up from $20.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $23.8 million in Q1 2026 and bottomed at $1.2 million in Q4 2024.
• The 5-year median for Total Current Liabilities is $7.2 million (2022), against an average of $8.5 million.
• The widest annual swing landed in 2024, when Total Current Liabilities sank 80.63%; it then soared 1575.0% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $11.1 million in 2022, then sank by 47.78% to $5.8 million in 2023, then plunged by 79.31% to $1.2 million in 2024, then jumped by 1575.0% to $20.1 million in 2025, then climbed by 18.47% to $23.8 million in 2026.
• The last three Total Current Liabilities figures came in at $23.8 million (Q1 2026), $20.1 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.

Peer Comparison